The emerging evidence on the potential relevance of CXCR1/2 signaling in the onset and progression of obesity-driven metabolic diseases and related complications is investigated in phase 2 clinical studies in obese Type 2 Diabetes (started at December 2020, EudraCT Nr. Here, CXCR1 is linked to obesity due to melanocortin 4 receptor deficiency.